AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Key Highlights
- ➤60 abstracts span AbbVie’s (ABBV) dermatology portfolio across six immune-mediated skin diseases
- ➤Upadacitinib delivers 52-week efficacy and safety data in severe alopecia areata Phase 3 trials
- ➤Zumilokibart Phase 2 APEX Part B results assess moderate-to-severe atopic dermatitis
- ➤Lutikizumab Phase 2 data evaluate symptom burden and quality of life in hidradenitis suppurativa
- ➤Risankizumab versus deucravacitinib 52-week results come from a Phase 4 psoriasis trial
Expert Statements
Ryan DeMasi, Vice president, global medical affairs, immunology, AbbVie
“At EADV, we are excited to share new data that further strengthen the growing evidence base across our dermatology portfolio, including SKYRIZI, RINVOQ and investigational therapies.”
Ryan DeMasi, Vice president, global medical affairs, immunology, AbbVie
“These findings underscore our ongoing research in advancing scientific understanding and delivering innovative treatment options that have the potential to meaningfully improve outcomes for patients across a broad spectrum of immune-mediated skin diseases.”
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress PR Newswire
* AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritis * New data for risankizumab and upadacitinib provide further evidence supporting efficacy and safety across diverse patient populations * Data evaluating investigational compounds lutikizumab and zumilokibart will also be presented, highlighting AbbVie's ongoing research in additional mechanisms of action NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapies, SKYRIZI(®) (risankizumab) and RINVOQ(®) (upadacitinib).
Get started
Create a free account to read the full story.